Immuneering Corporation (IMRX) Discusses Expanded Atebimetinib Development: Pancreatic and Anaplastic Thyroid Cancer Trials Transcript
Immuneering Corporation (IMRX) Discusses Expanded Atebimetinib Development: Pancreatic and Anaplastic Thyroid Cancer Trials - Slideshow
Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients
Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer
Immuneering Plans To Initiate Phase 2 Clinical Trial Evaluating Atebimetinib In Combination With Chemotherapy In Patients With Anaplastic Thyroid Cancer
Immuneering Enters Into Clinical Trial Collaboration And Supply Agreement To Supply Investigational MEK Inhibitor, Atebimetinib, For Two Astellas-Sponsored Studies Targeting Subset Of Pancreatic Cancer Patients
Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors
Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026
Immuneering Announces Its Atebimetinib's Data Shows Improvement In Activity Of PD-1 Checkpoint Blockade In RAS-Mutant Colorectal And Lung Cancer Models; Demonstrates 50% Durable Complete Regression In Colorectal Model
Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
Immuneering Has Promising Survival Data, Though Its Cash Discount Needs Scrutiny
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
Immuneering to Present at the ESMO Congress 2026
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
Immuneering To Present Data At American Association For Cancer Research Conference On Pancreatic Cancer: New Frontiers In Biology And Therapeutic Development
Immuneering to Participate in Upcoming Investor Conferences
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.